Vireo Growth (VREOF) Shares Outstanding (2020 - 2026)
Vireo Growth (VREOF) posted Shares Outstanding (Entity) of $1.1 billion for Q1 2026, up 43.89% sequentially from $734.7 million in Q4 2025, and up 211.42% YoY from $339.5 million in Q1 2025.
Vireo Growth (VREOF) Shares Outstanding (2020 - 2026) Analysis & Trends
Vireo Growth has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $1.1 billion in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 211.42% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 211.42% YoY) and the FY2025 annual result came in at $734.7 million, up 307.3% from the prior year.
- Shares Outstanding (Entity) advanced to $1.1 billion in Q1 2026 per VREOF's latest filing, from $734.7 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $1.1 billion in Q1 2026 and troughed at $110.0 million in Q4 2023.
- A 5-year average of $311.9 million and a median of $143.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) decreased 14.14% in 2023, then surged 360.88% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $128.1 million in 2022, then slipped by 14.14% to $110.0 million in 2023, then jumped by 63.98% to $180.4 million in 2024, then soared by 307.3% to $734.7 million in 2025, then surged by 43.89% to $1.1 billion in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $1.1 billion, $734.7 million, and $923.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 832.44 Mn |
| 10 | Vireo Growth | 493.25 Mn | 350.95 Mn | 95.30 Mn | 45.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Bn |
| Dec 31, 2025 | 734.74 Mn |
| Sep 30, 2025 | 949.82 Mn |
| Jun 30, 2025 | 559.10 Mn |
| Mar 31, 2025 | 366.80 Mn |
| Dec 31, 2024 | 180.39 Mn |
| Sep 30, 2024 | 201.38 Mn |
| Jun 30, 2024 | 143.58 Mn |
| Mar 31, 2024 | 143.13 Mn |
| Dec 31, 2023 | 135.24 Mn |
| Sep 30, 2023 | 141.33 Mn |
| Jun 30, 2023 | 128.13 Mn |
| Mar 31, 2023 | 128.13 Mn |
| Dec 31, 2022 | 128.13 Mn |
| Sep 30, 2022 | 128.12 Mn |
| Jun 30, 2022 | 128.11 Mn |
| Mar 31, 2022 | 128.11 Mn |
| Dec 31, 2021 | 123.81 Mn |
| Sep 30, 2021 | 126.36 Mn |
| Jun 30, 2021 | 125.56 Mn |